Statement from Emily’s Entourage regarding FDA approval of breakthrough therapy for Cystic Fibrosis
Today is a monumental day in the history of Cystic Fibrosis (CF) treatments and the history of medicine. The FDA announced its approval of the highly-anticipated triple combination therapy, Trikafta, developed by Vertex Pharmaceuticals, for 90% of the CF population ages 12 and older who have at least one copy of the most common CF mutation, F508del. Trifakta does not benefit those... Read More